Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab (Q38813080)

From Wikidata

Jump to navigation Jump to search

scientific article published on 9 October 2016

Language	Label	Description	Also known as
English	Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab	scientific article published on 9 October 2016

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6585752

Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab (English)

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6585752

phase III clinical trial

0 references

systemic lupus erythematosus

0 references

pharmacodynamics

1 reference

based on heuristic

inferred from title

Marta E Alarcón-Riquelme

3

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6585752

Michelle A. Petri

4

object named as

Michelle Petri

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

2

object named as

Joan T Merrill

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6585752

object named as

Yushi Liu

13

0 references

author name string

Robert W Hoffman

1

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6585752

Ernst R Dow

5

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6585752

Eric Nantz

6

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6585752

Laura K Nisenbaum

7

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6585752

Krista M Schroeder

8

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6585752

Wendy J Komocsar

9

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6585752

Narayanan B Perumal

10

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6585752

Matthew D Linnik

11

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6585752

David C Airey

12

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6585752

Guilherme V Rocha

14

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6585752

Richard E Higgs

15

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6585752

publication date

1 March 2017

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6585752

Arthritis & Rheumatology

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6585752

69

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6585752

3

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6585752

643-654

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6585752

Systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Regulated expression of BAFF-binding receptors during human B cell differentiation.

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations.

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controll

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Interferon and granulopoiesis signatures in systemic lupus erythematosus blood

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE.

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Diagnosis and risk stratification in patients with anti-RNP autoimmunity.

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Combined oral contraceptives in women with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Genetic susceptibility to systemic lupus erythematosus in the genomic era

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

The genetics of lupus: a functional perspective

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Summaries of Affymetrix GeneChip probe level data

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Direct multiplexed measurement of gene expression with color-coded probe pairs

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

WGCNA: an R package for weighted correlation network analysis

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Is my network module preserved and reproducible?

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Sample Sizes Required to Detect Interactions between Two Binary Fixed-Effects in a Mixed-Effects Linear Regression Model

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Human housekeeping genes, revisited

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Genetic analysis of the pathogenic molecular sub-phenotype interferon-alpha identifies multiple novel loci involved in systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Genetic analyses of interferon pathway-related genes reveal multiple new loci associated with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Towards the taxonomy of human disease.

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE).

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Randomized, Double-Blind, Placebo-Controlled Trial of the Effect of Vitamin D3 on the Interferon Signature in Patients With Systemic Lupus Erythematosus

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Network analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Densely interconnected transcriptional circuits control cell states in human hematopoiesis

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients

1 reference

https://api.crossref.org/works/10.1002%2FART.39950

21 January 2018

Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus

1 reference

https://pubmed.ncbi.nlm.nih.gov/27723281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The plasma cell signature in autoimmune disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/27723281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/ART.39950

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6585752

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6585752

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6585752

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38813080&oldid=2144075679"